Delving into the Latest Updates on COVID-19 Vaccine(Janssen) with Synapse

This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54).
Each participant will receive single or double doses of one of COVID-19 vaccines (Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine or Janssen Ad26.COV2.S COVID-19 vaccine) in the deltoid muscle of the non-dominant arm. Study Duration approximately 1 year. The main focus of this study is to compare the humoral and cellular immunological responses of the COVID-19 vaccines between bacteriologically confirmed TB patients under treatment vs healthy individuals.
This study is funded by the Wellcome Trust. The grant reference number is 220211/A/20/Z.

Start Date15 Apr 2023

Sponsor / Collaborator

University of Oxford

100 Clinical Results associated with COVID-19 Vaccine(Janssen)

Login to view more data

100 Translational Medicine associated with COVID-19 Vaccine(Janssen)

Login to view more data

100 Patents (Medical) associated with COVID-19 Vaccine(Janssen)

Login to view more data

11,378

Literatures (Medical) associated with COVID-19 Vaccine(Janssen)

31 Dec 2026·Journal of Maternal-Fetal & Neonatal Medicine

Vaccine acceptance in gravid patients in the COVID-19 era

Article

Author: Holmgren, Calla ; Phelps, Alexandra JD ; Snead, Karlie ; Hakimian, Dorothy ; Harrison, Rachel ; Schreiber-Gonzalez, Stephanie

OBJECTIVE:

To describe risk factors for declining antepartum vaccination, including the novel COVID-19 vaccine during the COVID-19 pandemic.

METHODS:

Retrospective cohort study including women delivering at a single center in the fall and winter of 2021. Patients without vaccine data were excluded. Baseline characteristics collected from the electronic medical record included maternal age, nulliparity, body mass index, insurance, and self-identified race/ethnicity. Those who accepted the COVID-19 vaccine were compared to those who declined. Separate comparisons were done to assess those who accepted and those who declined influenza and tetanus, diphtheria, pertussis (Tdap) vaccines as well. Statistical analysis was performed using Student's t-test, Fisher's exact test, chi square, and logistic regression. The regression model assessed the impact of patient characteristics on vaccine acceptance and was adjusted for age, nulliparity, body mass index, insurance, and race/ethnicity.

RESULTS:

Vaccine data was available for 772 patients. The rate of acceptance was 46.1% for COVID-19 vaccine, 58.0% for influenza vaccine, and 80.8% for Tdap vaccine. Those who accepted the COVID-19 vaccine were older (34.3 ± 3.8 years vs 33.0 ± 4.8 years, p < 0.001) and more frequently nulliparous (8.7% vs 2.9%, p < 0.001) than those declining it. Those accepting Tdap were also older (33.8 ± 4.3 vs 32.7 ± 4.9 years, p = 0.006). Insurance type differed across groups for all three vaccines (p < 0.001). Race differed between acceptance and refusal of the influenza and Tdap vaccines, but not the COVID-19 group. In the adjusted analysis, public insurance remained independently associated with reduced acceptance for COVID-19 (aOR 0.28, 95% CI 0.14-0.55) and influenza (aOR 0.38, 95% CI 0.20-0.73), but not for Tdap. Older age and nulliparity were independently associated with increased acceptance of COVID-19.

CONCLUSION:

Public insurance in pregnancy is associated with a decreased likelihood of vaccine acceptance for the COVID-19 and influenza vaccines. Specific efforts for understanding the motivations for declining vaccination are needed to develop strategies to improve uptake in this population.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Disparities and barriers to life-course vaccination in Ethiopia: Evidence from a household survey

Article

Author: Wgebriel, Abenezer ; Stulz, Virginia ; Awell, Tamrat ; Lakew, Yohanes ; Wondarad, Yakob ; Mihret, Mesfin ; Assefa, Geteneh Moges ; Aniefiok Uwah, Aniekeme ; Teferi, Mikiyas ; Negash, Kasahun ; Mulugeta, Betibebu ; Solomon, Silesh ; Kinfu Tilahun, Frehiwot ; Denekew, Baye ; Shimelis Biru, Kassahun ; Tarekegn Damtew, Michael ; Argaw, Mesele Damte ; Desalegn Muluneh, Muluken ; Semahegn, Agumasie

Achieving equitable access to life-course vaccination is a central objective of the global Immunization Agenda 2030 (IA2030). Ethiopia has made notable gains in routine immunization; however, disparities remain, particularly in underserved, pastoralist, and conflict-affected regions. This study assessed vaccination coverage, disparities, and barriers to service utilization across four regions of Ethiopia. A community-based cross-sectional survey was conducted in 57 woredas (districts) of Afar, Amhara, Oromia, and Tigray Regional states. Trained health workers administered digital questionnaires with GPS-enabled devices to caregivers, and eligible individuals subsequently received vaccines. The study enumerated 1.2 million households comprising 5.3 million individuals, including children under five, adolescent girls (9-14 y), pregnant women, and person aged 12 y and above. Descriptive and geospatial analyses were applied to examine coverage levels and disparities. The findings were revealed that 9.1% were zero dose, and 11.2% under-immunized, with measles-containing vaccine (MCV1) coverage at 88.3% among children aged 12-59 months. In addition, 79.6% of pregnant women were received tetanus-diphtheria (Td) vaccine, 75.3% of adolescent girls received Human Papilloma Virus (HPV) vaccine, while only almost half 53.8% of individuals aged 12 y and above received COVID-19 vaccine. Marked regional disparities were emerged: Afar recorded the highest zero-dose prevalence (24%), whereas Amhara and Tigray reported disparity levels below 10%. Despite progress in routine immunization, inequities persist, disproportionately affecting remote and marginalized populations. Addressing these gaps requires integrating geospatial microplanning, expanding mobile outreach, and applying culturally tailored demand-generation strategies to ensure equitable vaccine access and advance IA2030 targets.

31 Dec 2026·Human Vaccines & Immunotherapeutics

The role of age, sex, and ethnicity in vaccine trust, and sources of information in Canada: Findings from a national survey

Article

Author: Smith, Julia ; Tiwana, Muhammad H. ; Pham, Anh

Vaccine confidence plays a critical role in public health. Understanding demographic differences in trust and sources of vaccine information is essential for designing equitable communication strategies. We analyzed nationally representative summary data from Cycle 2 of the Canadian COVID-19 Vaccine Coverage Survey (CVCS), collected April-May2021 during the initial phase of the national vaccine rollout. The survey included adults aged 18 and older (n = 10,678). This study examines trust in vaccine safety, efficacy, and information sources across demographic factors such as age, gender, and visible minority status. Trust in vaccine safety and effectiveness was high overall (95% and 97%, respectively), peaking among older adults (96% and 98%) and lower among younger males (as low as 85% for perceived COVID-19 vaccine protection). In general, public health agencies were the most trusted sources of information (84%), followed by physicians and health scientists (70%); trust in vaccine manufacturers remained low (31%). Visible minority respondents were more likely to trust public health regulations (87% vs 83%) but also more likely to prefer natural immunity (20% vs. 14%) than non-visible minorities population. These findings provide a unique population-level snapshot of vaccine trust during the critical early phase of Canada's COVID-19 vaccine rollout. By identifying demographic differences in vaccine perceptions and information sources, our study offers an essential benchmark to inform future public health communication strategies and preparedness efforts.

1,229

News (Medical) associated with COVID-19 Vaccine(Janssen)

27 Feb 2026

·firstwordpharma.com

EU panel endorses Moderna's dual flu, COVID-19 vaccine

Moderna has locked horns with US regulators over its standalone seasonal flu vaccine in recent days, but the company appears to be enjoying a more receptive regulatory environment in Europe. On Thursday, the European Medicines Agency's (EMA) drug advisory panel issued a positive opinion for mCombriax (mRNA-1083), making it the first combined mRNA vaccine designed to protect adults 50 years and older against both seasonal influenza and COVID-19.The shot targets SARS-CoV-2 and three influenza strains – A/H1N1, A/H3N2 and B/Victoria – using mRNA molecules that encode viral surface proteins.The Phase III study used to support the filing included over 8000 participants aged 50-plus, and showed that mCombriax generated antibody responses against influenza and SARS-CoV-2 that were statistically non-inferior to co-administration of authorised vaccines, including Moderna's Spikevax for COVID-19 and either Fluzone HD or Fluarix for influenza, marketed by Sanofi and GSK, respectively.The EMA panel also noted that a study of a similar mRNA vaccine containing only the influenza component in mCombriax showed it could prevent influenza illness and trigger an adequate immune response. The most common side effects included injection-site pain, fatigue and muscle pain, and typically resolved within a median three days.Moderna has been struggling more with regulators in the US, however. The company voluntarily withdrew its application for mRNA-1083 last year after the FDA requested additional Phase III influenza efficacy data. The biotech had planned to resubmit a filing for the combo vaccine once the review for mRNA-1010, its standalone mRNA vaccine for influenza, was under way.Those plans hit a snag a few weeks ago after the FDA issued a refuse-to-file (RTF) letter for mRNA-1010, saying the company had not used an appropriate comparator during clinical testing. Moderna called the decision "inconsistent" with prior FDA feedback. However, after meeting with the company, the US regulator agreed to review the filing after all, setting a target review date of August 5.

VaccinePhase 3mRNAClinical ResultDrug Approval

12 Feb 2026

·www.drugs.com

COVID Vaccines During Pregnancy Not Linked To Autism

THURSDAY, Feb. 12, 2026 — Receiving the COVID-19 vaccine during pregnancy is not linked to any risk of autism or other brain development problems in children, a new study says. Researchers found no ties between mRNA COVID vaccines and child developmental issues, according to findings presented Wednesday at the Society for Maternal-Fetal Medicine’s annual pregnancy meeting in Las Vegas. “Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," senior researcher Dr. George Saade said in a news release. He’s chair of obstetrics and gynecology at Old Dominion University in Norfolk, Virginia. For the new study, researchers tracked 434 children for signs of autism or other developmental problems between 18 and 30 months of age. Half of the children were born to mothers who’d received at least one dose of the mRNA COVID vaccine during or immediately prior to pregnancy. The rest were born to mothers who hadn’t gotten the vaccine during pregnancy or the month before. Vaccinated and unvaccinated women were matched based on factors like where they gave birth, their delivery date, insurance status and race. Their kids’ brain development was tested when they were between 1.5 and 2.5 years of age. “This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy,” researcher Dr. Brenna Hughes said in a news release. She’s interim chair of obstetrics and gynecology at Duke University in Durham, North Carolina. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Sources Society for Maternal-Fetal Medicine, news release, Feb. 11, 2026

VaccinemRNAClinical Study

10 Feb 2026

·www.drugs.com

Substantial Number of Older Adults Do Not Think They Need Flu, COVID-19 Vaccines

TUESDAY, Feb. 10, 2026 -- More than four in 10 people older than 50 years (42 percent) have not gotten either a flu or COVID-19 vaccine, according to the results of a survey conducted by the University of Michigan National Poll on Healthy Aging. The survey, conducted online and by phone from Dec. 29, 2025, to Jan. 13, 2026, included responses from 2,964 U.S. adults ages 50 to 98 years. According to the poll results, 29 percent of respondents received both flu or COVID-19 vaccines, 27 percent received just the updated flu shot, and 42 percent received neither. The percentage receiving only the flu vaccine was higher across all age groups. Uptake was also consistently highest for the oldest adults (75 years and older: 76 percent received flu and 46 percent received COVID-19). For the COVID-19 vaccine, 49 percent of the surveyed older adults said it has been more than a year since their last dose, and 15 percent said they never received it. The most common reasons for not having received the vaccines were as follows: not thinking they need it (28 percent of those not receiving a flu vaccine and 29 percent not receiving a COVID-19 vaccine), worries about side effects (19 and 27 percent, respectively), and not thinking the vaccines are effective (18 and 19 percent, respectively). "These findings suggest that we must do a much better job helping people in their 50s and up understand that they will benefit from getting these updated vaccines each year, that the vaccine side effects are mild and short-lived, and that even if they later get infected and develop symptoms, vaccination means they won’t get as sick," Jeffrey Kullgren, M.D., M.P.H., the poll's director, said in a statement. More Information

VaccineClinical Result

100 Deals associated with COVID-19 Vaccine(Janssen)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07B	DB15857

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
COVID-19	United States	Janssen Pharmaceuticals, Inc.	27 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05515042 (Pubmed \| Lancet HIV)	Phase 2	COVID-19	694	BNT162b2 (people with HIV)	kijmmrxdtt(xgkpcclhmh) = veetypnghj eqwzfdvnyg (iralwiskfy, 8.6 - 11.7)	Positive	01 Feb 2026
NCT04998240 (Pubmed \| Clin Infect Dis)	Phase 4	COVID-19	367	BBIBP-CorVAd26.COV2.S + BBIBP-CorVAd26.COV2.S	zcezqvmfzn(sofcxbdyqe) = twjmbrwebz zjcbvksxxd (fiqavaigmk, 635.3 - 1014.3)	Non-inferior	22 Jul 2025
				BBIBP-CorV	zcezqvmfzn(sofcxbdyqe) = lhivuykozx zjcbvksxxd (fiqavaigmk, 150.8 - 272.1)
NCT04765384 (HORIZON 1, CTgov)	Phase 2	COVID-19	51	messenger Ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine+COVID-19 mRNA vaccine (Group 1 (Adults): Ad26.COV2.S 5*10^10 vp)	upzijaqdxi = eivuhavcbl chpajzinke (fvmxlmimox, hfhwijtbqr - xnknphibnz) View more	-	13 Nov 2024
				Ad26.COV2.S (Groups 2 and 3 (Adults): Ad26.COV2.S 5*10^10 vp)	upzijaqdxi = kxynulqoyw chpajzinke (fvmxlmimox, bznezafcoz - iuryedessm) View more
NCT04614948 (ENSEMBLE2 \| ENSEMBLE 2, CTgov)	Phase 3	COVID-19	31,835	adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S) (Double Blind Phase: Ad26.COV2.S)	itzczizuuf = bgsiprsrur ykbjdzxiyw (dwnxtpeklh, iwrgyjeoen - kvuzxjubaz) View more	-	09 Oct 2024
				placebo+Ad26.COV2.S (Double Blind Phase: Placebo)	itzczizuuf = rkghvbgkyy ykbjdzxiyw (dwnxtpeklh, ukzvilewrn - dvrhnfrsml) View more
NCT05007080 (HORIZON 2, CTgov)	Phase 2	COVID-19	304	Placebo (Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)	rqzssovgku = xshtqwibee inpahvxlgb (yklwprbdyv, goyuikyzum - wcpufzukdw) View more	-	23 May 2024
				Placebo (Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)	rqzssovgku = rfyiaenyob inpahvxlgb (yklwprbdyv, sqowjijwte - ejrkczyutb) View more
NCT04908722 (CTgov)	Phase 3	COVID-19	1,609	Ad26.COV2.S (Group 1: Ad26.COV2.S 9x10^10 vp)	vhfxnpkbrj(ikobkuyujg) = gowvvadhwv ulrkcxvwlr (ngfpikgyod, bqlsnknwxo - qxpjeqtuox) View more	-	23 May 2024
				Ad26.COV2.S (Group 2: Ad26.COV2.S 7x10^10 vp)	vhfxnpkbrj(ikobkuyujg) = lpsqsnxatg ulrkcxvwlr (ngfpikgyod, cfcmqjvjqf - prxgeodwgv) View more
NCT05091307 (CTgov)	Phase 3	COVID-19	861	Placebo+Ad26.COV2.S (Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)	xtueteoucx(jfqdwfeadc) = bggecqpngb wftibfpuau (hxpbevgzox, kbgcdojsya - wnfmluzngm) View more	-	08 Aug 2023
				Placebo+Ad26.COV2.S (Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)	xtueteoucx(jfqdwfeadc) = vioqzvdifo wftibfpuau (hxpbevgzox, mhojobwryl - ltdlpquyic) View more
NCT05047640 (20210641, CTgov)	Phase 3	COVID-19	58	BNT162b2 vaccine (BNT162b2 Vaccine Group)	mkmkboazvl = ojezadksxv dyqacjioxz (yfjmgcikkz, ehbprkccwg - hbktlyjdiw) View more	-	22 Jun 2023
				JNJ-78436735 Vaccine (JNJ-78436735 Vaccine Group)	mkmkboazvl = ufsyvusrzx dyqacjioxz (yfjmgcikkz, zkhzutpnmo - tcwolivnzv) View more
NCT04838795 (Sisonke study \| Sisonke (Together): OPEN LABEL, Pubmed \| BMJ Med)	Phase 3	Thrombosis	477,102	Ad26.COV2.S vaccine	cclohzrqer(bgrjbcazrf) = dyrzgnnrlg qixcfiqqzq (cpepnkgfxu, 20.5 - 44.0)	-	01 Mar 2023
NCT04999111 (Amplify, CTgov)	Phase 2	COVID-19	1,541	Ad26.COV2.S (Cohort 1: Ad26.COV2.S (5*10^10 vp))	stnyhismpp = ctsgkufcox mijxdaeimm (dgrnxkqwtp, eobhhzkadr - feazcngvmk) View more	-	05 Jan 2023
				Ad26.COV2.S (Cohort 1: Ad26.COV2.S (2.5*10^10 vp))	stnyhismpp = anakzgsphj mijxdaeimm (dgrnxkqwtp, tzzxtuqwfr - wwnfxrifpi) View more